Intervention for early diabetic nephropathy by mesenchymal stem cells in a preclinical nonhuman primate model

Xingxing An, Guangneng Liao, Younan Chen, Ai Luo, Jingping Liu, Yujia Yuan, Lan Li, Lichuan Yang, Hong Wang, Fang Liu, Guang Yang, Shounan Yi, Yuanmin Li, Jingqiu Cheng and Yanrong Lu

Abstract

Background: Diabetic nephropathy (DN) is one of the most severe chronic diabetic complications and the main cause of end-stage renal disease. Chronic inflammation plays a key role in the development of DN. However, few treatment strategies are available; therefore, new and effective strategies to ameliorate DN at the early stage must be identified.

Methods: Mesenchymal stem cells (MSCs) are characterized by anti-inflammatory and immune regulatory abilities. We developed a rhesus macaque model of DN and administered MSCs four times over 2 months. We measured blood glucose level, HbA1c, and levels of renal function parameters in the blood and urine, and cytokine levels in the kidney and blood circulatory system of rhesus macaques. Also, we analyzed the renal pathological changes of rhesus macaques. In vitro, we treated tubular epithelial cells (HK2) with 30 mmol/L glucose and 10 ng/mL human recombinant TNF-alpha (rhTNF-α) and explored the effects of MSCs on inflammation and Na⁺-glucose cotransporter 2 (SGLT2) expression in HK2.

Results: We found that MSCs decreased the blood glucose level and daily insulin requirement of DN rhesus macaques. Furthermore, MSCs had a dominant function in improving renal function and decreasing SGLT2 expression on renal tubular epithelial cells. Also, renal pathological changes were ameliorated after MSC treatment. Moreover, MSCs powerfully reduced inflammation, especially decreased the level of pro-inflammatory cytokine interleukin-16 (IL-16), in the kidney and blood circulatory system.

Conclusions: Our study is an important step to explore the mechanism of MSCs in ameliorating the early stage of DN, potentially through influencing SGLT2 expression and resulting in improved glycemic control and anti-inflammation. We hope these findings would provide insights for the clinical application of MSCs in DN.

Keywords: Diabetic nephropathy, Nonhuman primate model, Mesenchymal stem cells, Inflammation, SGLT2 inhibition

Background

Diabetes represents a source of worldwide health concerns, and the estimated number of people who will have diabetes by 2035 is 592 million. Diabetic nephropathy (DN), which is one of the most severe complications of diabetes [1], has been the main cause of end-stage renal disease in developed countries. Patients with type 1 diabetes typically develop DN after diabetes duration of 10 years but may be present at diagnosis of type 2 diabetes [2]. About 40% of type 2 diabetic patients develop DN [3–5]. DN is characterized by increased urinary albumin excretion, microalbuminuria, and reduced renal function indicated by an increased plasma creatinine concentration or a decreased glomerular filtration rate (GFR) [6]. DN is also an inflammatory disease, and the levels of inflammatory factors increase in patients with this disease [7].
Previously, we have established a preclinical non-human primate (Macaca mulatta) model of DN [8], which lays the foundation of this study for evaluating potential therapeutic strategies of DN. The treatments of DN mainly involve agents to ameliorate the disease. Na\(^+\)-glucose cotransporter 2 (SGLT2) inhibitors are new and efficient drugs that have been studied in some clinical trials aiming to treat DN based on the effect of SGLT2 on glucose reabsorption in the early proximal tubule [9], which accounts for \(\sim 97\%\) of renal glucose reabsorption under normal glycemic conditions. Based on evidence showing the restoration of tubuloglomerular feedback via the direct dilation of the afferent arteriole and indirect induction of vasoconstriction of the efferent arteriole, SGLT2 inhibitors increase the GFR [10]. Although the SGLT2 inhibitor has been shown to inhibit renal glucose reabsorption, new mechanisms of this drug, such as its influence on inflammation, are thought-provoking and require further investigation [11, 12], especially for DN, which is a low inflammation disease.

Mesenchymal stem cells (MSCs) represent an attractive regenerative therapy [13] and were first identified and isolated from bone marrow, and they are characterized by the ability to differentiate into tissues of mesodermal origin [14]. Currently, MSCs can be isolated from a variety of organisms and tissues [15–17]. Additionally, MSCs present anti-inflammatory and immune regulatory abilities [18]. A large number of studies have investigated the role of MSCs in many diseases, and they have been clinically approved for the treatment of graft-versus-host disease; moreover, 379 clinical trials of MSCs associated with diabetes (3 trials for chronic kidney disease) are registered on ClinicalTrials.gov, and they have been used to treat autoimmune diseases [19, 20]. Many animal experiment studies have applied MSCs for retinopathy [21], myocardial infarction [22], diabetes [23], and DN in rats and mice [24, 25]. Almost all studies of MSCs on DN have been conducted in rat or mouse models, which are genetically heterogeneous compared to humans, and the mechanisms of MSCs are not clear; therefore, studies in nonhuman primates are required because they could offer significant preclinical evidence of MSC applications.

Based on the abundant source, anti-inflammatory and immune regulatory features of MSCs, we administered MSCs in our rhesus macaque model of DN to explore the effects and mechanisms of MSCs on DN and answer the following questions: What are the interactions between MSCs and SGLT2 protein? Would MSC influence on glycemic control of DN rhesus macaques? Does MSCs transplantation result in SGLT2 inhibition thus contributing to reduced inflammation in kidneys? These questions are thought-provoking and worthy of investigation.

### Material and methods

#### Recombinant proteins and antibodies

Human recombinant TNF-alpha (rhTNF-α) (R&D Systems) was used at a final concentration of 10 ng/mL. All primary and secondary antibodies and their dilutions are described in Additional file 1: Table S1.

#### Rhesus macaques

Fifteen adult healthy rhesus macaques (male, aged 3–5 years) were obtained from Chengdu Ping'an Experimental Animal Reproduction Center (license no.: SCXK (CHUAN) 2014-013, Chengdu, China). The use and care of animals were in accordance with the guidelines of the Institutional Animal Care and Use Committee of Experimental Animal Center, West China Hospital, Sichuan University (Chengdu, China) (Protocol: 2014004A), which have been approved by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC). Rhesus macaques were randomly divided into a normal control group \((n = 3)\), which was fed a standard diet twice per day, and an experimental group \((n = 12)\), which were administered a single high dose of streptozotocin (STZ, 80 mg/kg) (Sigma-Aldrich) intravenously to induce diabetes as previously described [26]. Insulin was used to maintain the FBG level at 15–20 mmol/L in all diabetic rhesus macaques. To develop DN, a diet containing 10 g of salt and 60 g of peanuts was administered to diabetic rhesus macaques for at least 2 years as previously described [8]. Subsequently, rhesus macaques with DN were randomly divided into a normal saline-treated group \((DN + NS, n = 4)\) and a MSC-treated group \((DN + MSCs, n = 8)\); two DN rhesus macaques were euthanized for analyzing MSCs in organs at 1 week after MSC treatment. During the entire experiment, death or severe disease did not occur in any of the rhesus macaques.

#### Human umbilical cord-derived MSCs

Human umbilical cords were donated by women who underwent cesarean sections. Informed consent was obtained. Human umbilical cord-derived MSCs were freshly isolated from a single donor, characterized by MSC markers with flow cytometry, and established in terms of phenotypic profile, colony-forming potential, and differentiation potential to chondroblasts, osteoblasts, and adipocytes at Sichuan Stem Cell Bank, Chengdu, China (Additional file 1: Figure S1). In addition, viral factors, pathogenic organisms, and endotoxin levels of MSCs were monitored (Additional file 1: Table S1). MSCs were cultured with serum-free medium (Stem cell 05420MesenCultTM-XF Medium, StemRD). Cells between passages 3 and 5 were used for all experiments [27].
Delivery of MSCs
Freshly isolated and identified MSCs from a single donor were suspended in 100 mL normal saline (NS) and delivered at a density of $2 \times 10^6$ cells/kg to one DN rhesus macaque at an infusion rate of 45–50 drops/min. And each rhesus macaque was treated with MSC derived from a different umbilical cord. It took about 45–60 min to complete the infusion. A total four times of MSC transplantation were performed during 2 months. MSCs were labeled with 1 μg/mL CM-Dil cell tracker (Invitrogen), incubated at 37 °C for 5 min and 4 °C for 15 min, washed three times, and suspended in NS at the final MSC transplantation.

Blood analysis
Whole blood for routine examination and serum for biochemistry analysis were monitored every 3 months during the establishment of rhesus macaque model of DN, 1 day before MSC transplantation, and different months after MSC transplantation of rhesus macaque models. The levels of glucose, serum creatinine (Scr), blood urea nitrogen (BUN), and estimated glomerular filtration rate (eGFR) were analyzed using an automatic biochemistry analyzer (Hitachi, Tokyo, Japan).

Urine analysis
Urine samples were collected every 3 months after STZ injection and 1 month after MSC transplantation of rhesus macaques in individual primate metabolic cages. The levels of urinary microalbumin and urinary creatinine were assayed by a protein assay kit (Bio-Rad). The levels of urinary microalbumin and urinary creatinine excretion were defined as the ratio of urinary microalbumin to creatinine (UACR) in a range of 2.5–25 mg/mmol [6].

Renal histopathology
Percutaneous ultrasound-guided renal biopsy was performed in rhesus macaques before and 1 month after MSC or NS infusion. Hematoxylin and eosin (H&E), Masson’s trichrome (Masson), and periodic acid Schiff (PAS) staining and transmission electron microscopy (TEM) analyses of renal tissues were examined by two expert renal pathologists who were blinded to the experiments. Four fields of each section, and four sections per rhesus macaque were observed and quantified. Glomerular basement membrane thickness was determined by the orthogonal intercept method [28]. The renal histological changes for glomerulosclerosis, tubular dilation, mesangial matrix deposition, and interstitial fibrosis were evaluated semiquantitatively by a scoring system of 0–3, where 0 = no change, 1 = mild changes, 2 = moderate changes, and 3 = severe changes [29].

Immunohistochemistry
Renal sections were fixed with 4% paraformaldehyde, incubated with primary antibodies at 4 °C overnight and secondary antibody at 37 °C for 2 h, washed three times, and observed under a light microscope. Four fields of each section, and four sections per rhesus macaque were observed and quantified. The results of immunohistochemistry were analyzed by Image Pro Plus software.

Cell culture
Human proximal tubular cells (HK2) were obtained from ATCC (CRL-2190). To mimic the hyperglycemia and low-state inflammation environment, 30 mmol/L glucose with 10 ng/mL rhTNF-α (GT) was used. GT-treated HK2 cells were cocultured with MSCs in a Transwell plate at a 5:1 ratio (HK2: MSCs) for subsequent experiments. Each group had three replicates in one experiment, and all experiments in vitro were independently repeated three times unless indicated otherwise.

RNA extraction and real-time qPCR
RNA was extracted from renal biopsies and HK2 cells using a Promega SV Total RNA Isolation System (Promega) according to the manufacturer’s instructions. Primers were synthesized by Sangon Biotech (Shanghai, China). β-actin was used as the internal reference gene, and all primer sequences are listed in Additional file 1: Table S3. Real-time qPCR was carried out, and the relative fold change ($2^{-ΔΔCT}$) was calculated from the obtained CT values.

Magnetic Luminex assay
The levels of cytokines in rhesus macaque serum were measured by a Quantibody® Non-Human Primate Cytokine Array 1 (Raybiotech, Guangzhou, China).

Glucose uptake
The level of glucose in HK2 cell culture medium was measured by the glucose oxidase (GOD) method. Intracellular glucose levels were represented by $^{18}$F radioactivity in HK2 cells incubated with $[^{18}$F]-FDG (1 μCi/mL; 0.037 MBq/mL) in DMEM either in the presence or absence of high glucose for 2 h. $^{18}$F radioactivity was measured on a γ counter (Wallac).

Statistical analysis
Data were presented as the mean (± s.e.m.). Statistical analysis was performed using GraphPad 8.0 software. Statistical evaluation of two groups was performed using a Student t test or Mann–Whitney U test if data were not normally distributed. A two-way ANOVA was used to compare the differences between the groups of rhesus macaques and data collected at different time points. And the statistical analysis was corrected for repeated measures when comparing multiple measurements.
within subjects. A $p$ value less than 0.05 was considered statistically significant.

**Results**

**High-salt and high-fat diet induced early stage of DN in rhesus macaques**

The early stage of DN rhesus macaque model was established based on previous research in our laboratory [8]. Basal characteristics of all groups, including levels of biochemical parameters and quantified renal histological indices, are described in Table 1. Renal histological analyses of the kidney tissues, including H&E, Masson, and PAS staining (Fig. 1b), showed glomerulus hypertrophy, tubular dilatation, tubule collapse with the obliteration of the lumen, peritubular interstitial fibrosis, and thickened tubular basal lamina. TEM (Fig. 1c) showed increased mesangial matrix and thickened glomerular basement membranes (GBMs) in diabetic rhesus macaques after 2 years of a high-salt and high-fat diet.

**Rhesus macaques immunologically tolerated human umbilical cord-derived MSCs**

To evaluate whether rhesus macaques tolerate xenotransplantation of human MSCs, we tested their immune cells in peripheral blood, including the numbers of lymphocytes and monocytes, and the ratio of CD4+/CD8+ T cells (Additional file 1: Figure S2). We did not observe any prominent changes in the immune system of rhesus macaques after human umbilical cord-derived MSC infusion. Also, the weight and vital signs of rhesus macaques were stable after MSC transplantation. These data indicated the safety of xenotransplantation to rhesus macaques.

**Homing of MSCs to kidneys**

It is necessary to determine where MSCs migrate after MSC transplantation in rhesus macaques. One week after the final transplantation of CM-Dil-labeled MSCs, two DN rhesus macaques were sacrificed and analyzed for red fluorescence in organs. We observed that the strongest fluorescence signal was in the lung, followed by the kidney (Additional file 1: Figure S3). After confirming the successful migration of MSCs to the kidney, we explored the duration that the infused MSCs remained in the kidney. One week and one month after the last injection of MSCs, we performed percutaneous renal biopsy of all rhesus macaques and observed renal sections under fluorescence microscopy. One week after MSC transplantation, we observed red fluorescence in the cytoplasm and intact cell membrane, whereas fluorescence was not observed in the renal tissue from normal or normal saline-injected rhesus macaques. One month after MSC transplantation, red fluorescence was still observed in the renal tissue, which especially arranged along tubular epithelial cells (Fig. 2A). Due to the lack of specific markers of MSCs, we used a marker of epithelial cells (E-cadherin) to help determine whether the red fluorescence was from CM-Dil-labeled MSCs and not from the resident cells in the kidney. Interestingly, MSCs were observed around tubular epithelial cells (E-cadherin-positive) (Fig. 2B). Notably, the number of MSCs per field dropped significantly between 1 week and 1 month after MSC infusion (Fig. 2C). These data lay the foundation of further research, such as that to explore the effects of MSCs on tubular epithelial cells.

**MSCs improved glycemic control and renal function of rhesus macaques**

After confirming that MSCs could migrate to the kidney, we then explored the effects of MSCs on glycemic control and renal function of rhesus macaques. Although we used insulin to maintain a proper blood glucose level (15–20 mmol/L) of rhesus macaques, it was necessary to assess the effect of MSC on glycemic control which is always a primary concern of treatments of diabetic complications. Interestingly, we observed that the average level of fasting blood glucose (Fig. 3a) and HbA1c (Fig. 3b), and daily requirement of insulin (Fig. 3c) in rhesus macaques with MSC treatment were significantly lower than those with normal saline infusion. During MSC transplantation, the levels of Scr (Fig. 3d) and BUN (Fig. 3e) decreased. However, the protective effect of MSCs did not persist over time because we observed that the levels of Scr and BUN tended to increase again after only one course of MSC treatment in rhesus macaques. The level of eGFR increased after MSC transplantation but decreased after NS infusion (Fig. 3f). The levels of UA (Fig. 3g), urine microalbumin (Fig. 3h), and UACR (Fig. 3i) declined significantly after MSC transplantation and were much lower than those after NS infusion. These results suggested that MSCs ameliorated the progression of diabetic nephropathy in combination with insulin and indicated a possibility that the effects of MSC on improved renal function might partly be attributed to improved glycemic control.

Ultrasound is crucial for evaluating the patterns of vascularization of the kidney and contributes to the diagnosis and prediction of the early progression of chronic kidney disease [30]. Only rhesus macaques in the MSC treatment group were analyzed for renal vascularization by contrast-enhanced ultrasound (CEUS) before and after MSC treatment. We observed that the mean transit time, time to peak, and area under the descending curve decreased after MSC transplantation (Additional file 1: Figure S4), which suggested an improved renal perfusion and clearance. However, CEUS analysis should also be performed in rhesus macaques before and after normal
Table 1 The baseline characteristics of rhesus macaques

| Group          | Normal (n=3) | DN+NS (n=4) | DN+MSCs (n=8) |
|----------------|-------------|-------------|---------------|
| ID             | 05145       | 05265       | 04053         |
|                | 09388       | 06145       | 05339         |
|                | 10475       | 09475       | 06431         |
|                | 05593       | 09475       | 07343         |
|                | 04053       | 09011       | 10091         |
| Gender         | Male        | Male        | Male          |
| Body weight (Kg)| 4.5±0.2    | 4.7±0.2     | 4.6±0.2       |
| CREA (μmol/L)  | 46.9±8.43   | 101±113.4   | 107.8±115.1   |
| BUN (mmol/L)   | 4.7±0.47    | 12.19±15.42 | 8.66±10.92    |
| Uric Acid (μmol/L)| 1±1        | 2.75±1.71   | 3±4           |
| LDL-C (mmol/L) | 1.5±0.11    | 1.66±1.21   | 1.07±1.48     |
| HDL-C (mmol/L) | 2.34±0.6    | 4.64±3.73   | 4.97±4.9      |
| Triglycerides (mmol/L)| 0.5±0.6| 0.62±0.14 | 0.75±0.65    |
| FBG (mmol/L)   | 6.3±5.8    | 19.71±19.51 | 18.86±20.08   |
| HbA1c (%)      | 5.7±5.9    | 11.5±10.7   | 9.5±10.2      |
| Daily insulin (U)| 0±0.5     | 1.5±1.2     | 1±1.2         |
| Urinary microalbumin (mg/L)| 0±0.03  | 1.3±0.25    | 1±1.2         |
| Urinary creatinine (μmol/L)| 1.451 | 1729±1525 | 1828.75±249.2 |
| Glomerulosclerosis (score)| 0±0     | 2±2         | 2±2           |
| Mesangial matrix deposition (score)| 0±0 | 1±2         | 1±1.2         |
| Tubular dilation (score)| 0±0 | 2±2         | 2±2           |
| Interstitial fibrosis (score)| 0±0 | 2±2         | 2±2           |

CREA serum creatinine, BUN blood urea nitrogen, LDL-C low-density lipoprotein, HDL-C high-density lipoprotein, CHOL cholesterol, FBG fasting blood glucose, HbA1c glycosylated hemoglobin. Score of renal histological changes: 0 = no change, 1 = mild changes, 2 = moderate changes, and 3 = severe changes

*<p><0.05: DN+NS vs. Normal, DN+MSCs vs. Normal
saline infusion to enhance the evidence that improved renal perfusion was ascribed to MSC treatment.

**MSCs ameliorated renal pathological changes**

Before and 1 month after NS or MSC transplantation, percutaneous renal biopsy was conducted on rhesus macaques, and renal pathological changes were analyzed. H&E staining showed noticeable improvements of renal pathological changes in DN rhesus macaques after MSC transplantation, including amelioration of glomerular hypertrophy, tubular dilatation, and peritubular interstitial fibrosis (Fig. 4e). In contrast, the pathological damages continued after NS infusion, which were indicated by a further glomerulosclerosis and tubular dilatation (Fig. 4b, c). Masson staining showed that rhesus macaques with DN had noticeable glomerulosclerosis and tubular

---

**Fig. 1** Rhesus macaques presenting an early stage of DN. **a** Timeline of the study. **b** Histological staining of renal tissues. Glomerular hypertrophy, tubular dilatation, and peritubular interstitial fibrosis were indicated by arrows. **c** TEM of renal tissues. Thickened glomerular basement membranes are indicated by red arrow and asterisk. **d-g** Quantified renal histological indices at baseline and 2 years later. GBM: glomerular basement membrane. Normal: normal and nondiabetic rhesus macaques; DN: rhesus macaques with diabetic nephropathy. Scale bar = 50 μm. Magnification of TEM: 1.2 k. Each bar represents the mean ± s.e.m. Four fields of each section, four sections per rhesus macaque were observed and quantified, and the number of rhesus macaques analyzed in each group: Normal (n = 3), DN (n = 12). ****p < 0.0001: normal group versus DN group after 2 years.
interstitial fibrosis (Fig. 4g, i) compared with normal rhesus macaques (Fig. 4f). PAS staining showed Bowman’s capsule hyperplasia, an expanded mesangial matrix, and an increased number of mesangial cells in rhesus macaques with DN (Fig. 4l, n). MSC was associated with a stabilization of fibrosis (Fig. 4j) and mesangial matrix expansion (Fig. 4o) in contrast to the saline-treated group in which these indices worsened (Fig. 4h, m).

TEM of biopsied kidney tissues indicated differences between normal rhesus macaques and those with DN. Specifically, with regard to glomerular structures, the loose and dense layers of GBM vanished and were replaced by one mixed thickened layer; a portion of interstitial capillary walls became thinner, discontinuous, and roughened; the number of mesangial cells increased; and the matrix was increased in rhesus macaques with DN (Fig. 4q, s) compared to that in normal rhesus macaques (Fig. 4p). Regarding the renal tubule structures, the tubular epithelia swelled and tubular interstitial fibrosis was observed in the rhesus macaques with DN (Fig. 4v, x).

We observed a worsening trend of renal pathological changes after NS infusion, including that the thickened

---

**Fig. 2** Fluorescence microscopy of MSCs in rhesus macaques. MSCs were labeled by CM-Dil (red fluorescence) before infusion to rhesus macaques. **a** Renal biopsies at 1 week and 1 month after MSC transplantation. **b** Immunostaining of kidney tissues at 1 month after MSC transplantation. **c** Quantification of number of MSCs per field at 1 week and 1 month after MSCs infusion. MSCs were labeled by CM-Dil (red), tubular epithelial cells were stained by E-cadherin (green), and cell nuclei were stained by Hoechst (blue). Scale bar of **a** = 10 μm and scale bar of **b** = 20 μm. Each bar represents the mean ± s.e.m. Four fields of each section, four sections per rhesus macaque were observed and quantified, and the number of rhesus macaques was analyzed in each group: Normal (*n* = 3), DN + NS (*n* = 4), DN + MSCs (*n* = 8).
GBM became worse (Fig. 4r) and tubular interstitial fibrosis increased (Fig. 4w). In contrast, after MSC transplantation, rhesus macaques with DN showed improvements in renal structures, including thinner GBM (Fig. 4t) and reduced tubular interstitial fibrosis (Fig. 4y).

MSCs reduced SGLT2 expression and decreased inflammation in the kidney and the whole circulatory system

Anti-inflammation has been reported as the most attractive feature of MSCs, which was also verified by our results. The gene expression levels of IL-1β, TNF-α, TGF-β, and CCL-5 in kidney tissues decreased. Strikingly, the levels of protein specifically expressed on tubular epithelial cells (SGLT2) and pro-inflammatory cytokine IL-16, which was released mainly by epithelial cells and immune cells, were sharply abrogated after MSC transplantation, whereas the levels of IL-6 and IL-8 increased after MSC transplantation (Fig. 5A). Consistent with the gene expression changes, the protein expression levels of IL-1β, IL-16, TNF-α, CTGF, and SGLT2 reduced after MSC transplantation, and the protein level of IL-6 increased after MSC injection (Fig. 5B).

We further explored whether MSCs were sufficient to decrease a low state of inflammation in the whole circulatory system. We analyzed the levels of 10 inflammatory cytokines in blood serum, and the results showed that except for GM-CSF, the other cytokines decreased immediately at 1 week after the first injection of MSCs. At the seventh and 12th week, the levels of all 10 inflammatory

Fig. 3 Protective effects of MSCs on rhesus macaques. Parameters related to glycemic control and renal function were measured and analyzed before (month 0), during (months 1, 2), and after (months 3, 6, 9, 12) normal saline or MSC infusion. a Fasting blood glucose (FBG), b HbA1c, c daily required insulin dose, d Levels of serum creatinine (Scr), e blood urea nitrogen (BUN), f estimated glomerular filtration rate (eGFR), g uric acid, h urine microalbumin, and i ratio of urinary microalbumin to creatinine (UACR) were analyzed. NS: normal saline; MSCs: mesenchymal stem cells. Each bar represents the mean ± s.e.m. Normal (n = 3), DN + NS (n = 4), DN + MSCs (n = 6). *p < 0.05: before versus after in DN + MSC group and DN + MSC group versus normal group. #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001: DN + NS group versus DN + MSC group after NS or MSC transplantation.
Fig. 4  Histopathology analysis of tissues from rhesus macaques. Pathological changes were observed under a light microscope (a) and transmission electron microscope (b). Normal rhesus macaque glomerulus and tubes (a, f, k, p, and u); rhesus macaques with DN before normal saline infusion (b, g, l, q, and v) or MSC transplantation (d, i, s, and x). Further expanded mesangial matrix and progressive peritubular interstitial fibrosis after normal saline infusion (c, h, m, r, and w), and ameliorated glomerular basement membranes, mesangial matrix, and peritubular interstitial fibrosis after MSC transplantation (e, j, o, t, and y). The arrows and red asterisks represent pathological areas.

Quantified renal histological indices before and 1 month after NS or MSC transplantation. GBM: glomerular basement membrane; NS: normal saline; MSCs: mesenchymal stem cells. Scale bar of pictures in a: 50 μm; magnification of TEM: 1.2 k. Each bar represents the mean ± s.e.m. Four fields of each section, four sections per rhesus macaque were observed and quantified, and the number of rhesus macaques was analyzed in each group: Normal (n = 3), DN + NS (n = 4), DN + MSCs (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001: before versus after in DN + MSC group. #p < 0.05, ##p < 0.01, ###p < 0.001: DN + NS group versus DN + MSC group after NS or MSC transplantation.
Fig. 5 (See legend on next page.)
factors were less than those before MSC transplantation. This anti-inflammatory role lasted 32 weeks (Fig. 6).

**GT-induced inflammation in HK2**

Previously, we established that a high level of glucose and palmitic acid induced a glucolipotoxicity damage model of endothelial cells and verified the protective effects of MSCs on glucolipotoxicity-injured endothelial cells [31]. In this study, we built a damaged model of renal epithelial cells (HK2 cells) to explore the effects of MSCs on HK2 cells. GT was used to induce damage model of HK2 cells on the basis that there was a hyperglycemic and inflammatory microenvironment in the kidney. CCK-8 assay suggested that cell viability
decreased (Fig. 7a), and flow cytometry indicated that the level of ROS production (Fig. 7b) and the ratio of cell apoptosis (Fig. 7c) increased in a time-dependent manner after GT treatment. In addition, the gene expression levels of inflammatory cytokines increased as early as 3 h after GT stimulation (Fig. 7d).

**MSCs decreased SGLT2 expression and inflammation in HK2**

The protein expression levels of FN, SGLT2, IL-1β, TNF-α, and phosphor-Nuclear factor-kappa B p65 (p-NF-κB p65) in HK2 cells were decreased after co-culture with MSCs for 72 h. Notably, MSCs increased the IL-6 level in GT-treated HK2 cells (Additional file 1: Figure S5a-b). Additionally, MSCs partly improved the function of epithelial cells by increasing the level of nitric oxide (Additional file 1: Figure S5c) and reduced glucose reabsorption (Additional file 1: Figure S5d).

The SGLT2 inhibitor canagliflozin has been investigated for its role in renal function [32]. In our research, canagliflozin was a positive control to explore SGLT2 inhibition. We chose a proper concentration of canagliflozin (100 nM) by analyzing its effect on cell viability (Fig. 8a) and glucose reabsorption (Fig. 8b) in GT-treated HK2 cells. SGLT2 relies on ATP to transport glucose, thus the reason for SGLT2 inhibition must be determined. Does the inhibition result from a decrease in ATP or SGLT2 expression? Hence, we measured the ATP level and found that both MSCs and canagliflozin increased the ATP level in HK2 cells (Fig. 8c). Also, we observed that the expression levels of FN, SGLT2, and p-NF-KB p65 in HK2 cells decreased either in co-culture system of canagliflozin or MSCs for 72 h (Fig. 8d, e).

**Discussion**

For the first time, we explored the effects of MSCs on inflammation and SGLT2 expression in nonhuman primates with DN, and we also investigated the potential mechanisms of MSCs (Fig. 9). In our research, we developed a rhesus macaque model of DN and performed MSC transplantation four times over 2 months. By analyzing the labeled MSCs in organs, we determined that MSCs could migrate to the kidneys and play a role there. Because the expression levels of SGLT2 in renal sections of rhesus macaques who received MSCs were...
significantly lower than those who had NS injection, we speculated that MSCs had effects on regulating SGLT2 expression on renal tubular epithelial cells.

Although the improvement in glycemic control of DN rhesus macaques after MSC treatment may be explained by extra-renal effects, it also raises the interesting possibility that one reno-protective mechanism of MSC therapy is to inhibit diabetes-associated upregulation of SGLT2 in renal proximal tubular epithelial cells. Also, we observed reduced SGLT2 expression in renal sections and improved renal function after MSC transplantation, and these results were consistent with the previous findings in which the SGLT2 inhibitor was shown to rebalance tubuloglomerular feedback and improve eGFR [33]. On the basis of these observations, we speculate that the change of SGLT2 expression likely to be a result than a cause of MSCs, which strongly implicate that MSCs are more pleiotropic and better for clinical application than the use of SGLT2 inhibitor alone.

We explored the protective effects of MSCs on DN of nonhuman primates rather than small animals [34] and provided a basis for future preclinical research, which is essential for the clinical application of MSCs. MSCs inhibited SGLT2 expression and decreased the blood glucose level, ameliorated pathological changes in renal tissues, and reduced inflammation in the kidneys and blood circulatory system, which contributed to improved renal function. Our results were consistent with other studies that used inflammation as a therapeutic target and showed that decreased inflammation improved vascular function in kidney disease [35]. However, we provided new insights into anti-inflammation effects of MSCs potentially through inhibiting SGLT2 expression.

Diabetic nephropathy is a microvascular complication of diabetes, and we observed that MSC transplantation improved renal perfusion and clearance. Previously, we explored the effects of MSCs on endothelial cells and verified the protective effects of MSCs on high glucose- and palmitic acid-injured endothelial cells, which helped to demonstrate the functions of MSCs on blood vessels. In this study, we explored another important cell type in kidneys, tubular epithelial cells. Due to the different physiological characteristics between tubular epithelial cells and blood vessel endothelial cells, fatty acid would not directly interact with renal tubular epithelial cells. In addition, TNF-α has been demonstrated to indicate...
inflammation in DN [36]. Hence, under these conditions, a high level of glucose and palmitic acid does not fit to induce a damage model of renal tubular epithelial cells in this study; instead, glucose and rhTNF-α were proper to mimic the hyperglycemia and inflammatory microenvironment in kidneys. Both MSC and SGLT2 inhibitor canagliflozin decreased GT-induced inflammation of HK2 cells; however, co-culture of HK-2 and MSC under GT condition was associated with a striking induction of IL-6 in both cell types, which require further research about the potential effect and mechanism.

The main limitations of this study include that the high cost of nonhuman primates is an obstacle of exploring more information about the duration of MSCs that stayed at various organs. In addition, although we established the early stage of DN rhesus macaque model according to the standard diagnosis of human DN, which is featured by microalbuminuria and UACR in a range of 2.5–25 mg/mmol, the level of albuminuria in DN groups remained low throughout the experiment, which did not totally mimic the progressive changes of albuminuria with time in human DN. Although we analyzed the immune cells and vital signs of rhesus macaques after MSC transplantation, we did not measure the antibody levels of anti-human IgA, IgM, and IgG, so the immunogenicity of the human MSC in rhesus macaque is not fully determined.

**Conclusions**

In conclusion, our study is an important step to explore the mechanism of MSCs in ameliorating the early stage of DN, which possibly through influencing SGLT2 expression and resulting in improved glycemic control and decreased inflammation. We hope our research provides a basis for inspiring new developments in the future.

**Additional file**

**Additional file 1: Figure S1.** The surface markers and multiple differentiation potentials of hUC-MSCs. a Flow cytometric analysis of cell markers of MSCs. b Osteogenic differentiation and adipogenic differentiation of MSCs were determined by alizarin red staining and Oil red O staining. Scale bar= 50 μm. **Figure S2.** The rhesus macaques tolerated the xenogeneic hUC-MSCs. a Flow cytometric analysis of the ratio of the CD4+/CD8+ cells. b Quantification of flow cytometric analysis. c Weight of rhesus macaque. d-f Sum and sort counting of lymphocytes (LYM), monocytes (MONO), and neutrophils (NEU) in blood of rhesus macaques.
Fluorescence microscopy of CM-Dil-labeled MSCs in rhesus macaques. Red fluorescence in organs of two rhesus macaques with diabetic nephropathy at 1 week after MSCs infusion. Scale bar (red) = 50 μm; scale bar (white) = 20 μm. Each bar represents the mean±s.e.m.. Four fields of each section, and 4 sections per rhesus macaque were observed and quantified. Figure S4. Contrast-enhanced ultrasonography of the kidneys of rhesus macaques with MSC treatment. A images of contrast-enhanced ultrasound (CEUS) of the kidney before and 1 month after MSC transplantation. B Analysis of the rise time (RT), mean transit time (MTT), time to peak (TTP), and time from peak to one half (TPH). C Quantification of the area under the descending curve (AUC). Each bar represents the mean±s.e.m., n=6. * p < 0.05. Figure S5. Effects of MSCs on HK2 cells at 72 hours after GT. A Western blot analysis of protein expression levels in GT-treated HK2 cells with and without MSC coculture. B Quantification of western blot analysis of protein expressions. C Effect of MSCs on the NO production ability in HK2 cells. D Levels of glucose in the culture medium of HK2 cells analyzed by the oxidase method. Each bar represents the mean±s.e.m., n=3/group. * p < 0.05; ** p < 0.01; # p < 0.05. Table S1. Primary and secondary antibodies. Table S2. hUC-MSCs Quality Inspection report. Table S3. The list of primers sequences. (DOC 15731 kb)

Acknowledgements

We thank the members in the NHC Key Laboratory of Transplant Engineering and Immunology, West China Hospital (Sichuan University, Chengdu, China) for the experimental advice. We thank the members in the NHC Key Laboratory of Transplant Engineering and Immunology, West China Hospital (Sichuan University, Chengdu, China) for the experimental advice. We thank the members in the NHC Key Laboratory of Transplant Engineering and Immunology, West China Hospital (Sichuan University, Chengdu, China) for the experimental advice. We thank the members in the NHC Key Laboratory of Transplant Engineering and Immunology, West China Hospital (Sichuan University, Chengdu, China) for the experimental advice. We thank the members in the NHC Key Laboratory of Transplant Engineering and Immunology, West China Hospital (Sichuan University, Chengdu, China) for the experimental advice.

Authors’ contributions

VA contributed to the experimental design, collection and analysis of the data, and writing and revision of the manuscript. GL, AL, LT, HW, YL, LI, LG, and YL contributed to the collection of the data. YC, JL, FL, and SY contributed to the collection of the data. YC, JL, FL, and SY contributed to the collection of the data. YC, JL, FL, and SY contributed to the collection of the data. YC, JL, FL, and SY contributed to the collection of the data.

Funding

This work is supported by grants from the National Natural Science Foundation of China (grant number 81370824 and 81870609), the National Key Clinical Project, and Key R&D Projects of Sichuan Science and Technology Department (2018ZD009).

 Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate

Adult healthy experimental rhesus macaques were provided by the Chengdu Ping'an Experimental Animal Reproduction Center (License No.: SCXK (CHUAN) 2014-013, Chengdu, China). The use and care of animals were in accordance with the guidelines of the Institutional Animal Care and Use Committee of Experimental Animal Center, West China Hospital, Sichuan University (Chengdu, China) (Protocol: 20100404A), which have been approved by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Key Laboratory of Transplant Engineering and Immunology, NHFPC, West China Hospital, Sichuan University, Chengdu, China. 2Animal Center, West China Hospital, Sichuan University, Chengdu, China. 3Sichuan Neo-Life Stem Cell Biotech Inc, Chengdu, China. 4Department of Nephrology, West China Hospital, Sichuan University, Chengdu, China. 5Department of Ultrasound, West China Hospital, Sichuan University, Chengdu, China. 6Center for Transplant and Renal Research, Westmead Institute for Medical Research, The University of Sydney, Camperdown, NSW, Australia.

Received: 8 May 2019 Revised: 27 August 2019 Accepted: 29 August 2019 Published online: 02 December 2019

References

1. Nazar CM. Diabetic nephropathy: principles of diagnosis and treatment of diabetic kidney disease. J Nephrophenpharmacol. 2014:3:15–20.
2. American Diabetes Association. Microvascular complications and foot care: standards of medical care in diabetes-2019. Diabetes Care 2019;42:5124–5138.
3. Tuttle KR, Bakris GL, Bilous RW, Chiang II, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA consensus conference. Am J Kidney Dis. 2014;64:510–33.
4. de Boer IH. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:24–30.
5. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999;341:1127–33.
6. Fineberg D, Jandelet-Dahm KA, Cooper ME. Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol. 2013;9:713–23.
7. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:198–107.
8. Wang D, Liu J, He S, Wang C, Chen Y, Yang L, et al. Assessment of early renal damage in diabetic rhesus monkeys. Endocrine. 2014;47:783–92.
9. Vallon V, Platt KA, Canard R, Schroth J, Whalley J, Thomson SC, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22:104–12.
10. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255–70.
11. Prachtichizzo F, De Nigris V, Micheloni S, La Sala L, Ceriello A. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammation the neglected component? Diabetes Obes Metab. 2018;20:2515–22.
12. Diaz-Rodriguez E, Agra RM, Fernandez AS, Adrio B, Garcia-Caballero T, Gonzalez-Juanatey JR, et al. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. Cardiovasc Res. 2018;114:336–46.
13. Hickson LJ, Eirin A, Lerman LO. Challenges and opportunities for stem cell therapy in patients with chronic kidney disease. Kidney Int. 2016;89:767–78.
14. Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luria EA, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974;2:83–92.
15. Im GI, Shin YW, Lee KB. Do adipose tissue-derived mesenchymal stem cells have the same osteogenic and chondrogenic potential as bone marrow-derived cells? Osteoarthr Cartil. 2005;13:845–53.
16. Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood. 2001;98:2366–402.
17. Kawashima N. Characterisation of dental pulp stem cells: a new horizon for tissue regeneration? Arch Oral Biol. 2012;57:1439–58.
18. Shi Y, Wang Y, Li Q, Liu K, Hou J, Shao C, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018;14:493–507.
19. Trounson A. New perspectives in human stem cell therapeutic research. BMC Med. 2009;7:29.
20. Haller MJ, Viener HL, Wasserfall C, Brusko T, Atkinson MA, Schatz DA. Autologous umbilical cord blood infusion for type 1 diabetes. Exp Hematol. 2008;36:710–5.
21. Engerman RL, Kem TS. Retinopathy in animal models of diabetes. Diabetes Metab Rev. 1995;11:109–20.
22. Lee RH, Pulin AA, Min JS, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous hMSCs improve myocardial infarction in mice because cells emboled in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5:54–63.
23. Shuai W, Yi L, Jinghong Z, Jingbo Z, Yunjian H. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model. Biol Blood Marrow Transplant. 2013;19:538–46.
24. Mohammadian M, Shamsaiejan K, Lotfi NP, Talebi M, Jahedi M, Nickkhah H, et al. Mesenchymal stem cells: new aspect in cell-based regenerative therapy. Adv Pharm Bull. 2013;3:433–7.
25. Fernando E, Marcelo E, Valeska S, Fabian P, Alejandro YE, Daniel C, et al. Endovenous administration of bone-marrow-derived multipotent mesenchymal stromal cells prevents renal failure in diabetic mice. Biol Blood Marrow Transplant. 2009;15:1354–65.
26. Jin X, Zeng L, He S, Chen Y, Tian B, Mai G, et al. Comparison of single high-dose streptozotocin with partial pancreatectomy combined with low-dose streptozotocin for diabetes induction in rhesus monkeys. Exp Biol Med (Maywood). 2010;235:877–85.
27. Liu X, Zheng P, Wang X, Dai G, Cheng H, Zhang Z, et al. A preliminary evaluation of efficacy and safety of Wharton’s jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cell Res Ther. 2014;5:57.
28. Jensen EB, Gundersen HJ, Osterby R. Determination of membrane thickness distribution from orthogonal intercepts. J Microsc. 1979;115:19–33.
29. Sugimoto H, LeBleu VS, Bosukonda D, Keck P, Taduri G, Bechtel W, et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med. 2012;18:396–404.
30. Takata T, Koda M, Sugihara T, Sugihara S, Okamoto T, Miyoshi K, et al. Left renal cortical thickness measured by ultrasound can predict early progression of chronic kidney disease. Nephron. 2016;132:25–32.
31. An X, Li L, Chen Y, Luo A, Ni Z, Liu J, et al. Mesenchymal stem cells ameliorated glucolipotoxicity in HUVECs through TSG-6. Int J Mol Sci. 2016;17:483.
32. Heerspink HJ, Desai M, Jardine M, Balis D, Meeninger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017;28:368–75.
33. de Boer IH, Kahn SE. SGLT2 inhibitors—sweet success for diabetic kidney disease? J Am Soc Nephrol. 2017;28:287–10.
34. Ji AT, Chang YC, Fu YJ, Lee OK, Ho JH. Niche-dependent regulations of metabolic balance in high-fat diet-induced diabetic mice by mesenchymal stromal cells. Diabetes. 2015;64:926–36.
35. Walther CP, Navaneethan SD. Inflammation as a therapeutic target to improve vascular function in kidney disease. J Am Soc Nephrol. 2017;28:723–5.
36. Gurley SB, Ghosh S, Johnson SA, Azushima K, Sakkari RB, George SE, et al. Inflammation and immunity pathways regulate genetic susceptibility to diabetic nephropathy. Diabetes. 2018;67:2096–106.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.